Comprehensive analysis of 4.3 million crawler requests shows major frontier bots never request Markdown, leaving Cloudflare Markdown for Agents with zero impact on AI search citations.

PHOENIX, AZ

 AnswerShare, the pioneer of the AI Translation Layer released findings from a new study demonstrating that serving Markdown content via tools like Cloudflare Markdown for Agent has no impact on frontier AI crawler behavior, search engine citations, or recommendations.

Despite claims from industry experts that Markdown solves HTML bloat and makes pages easier for AI to ingest, the study shows that major frontier bots simply do not request Markdown format.

Methodology and Findings

Leveraging an active weekly crawl volume of approximately 1.5 million requests across multiple edge-controlled domains, the study conducted a rigorous, data-driven evaluation.

The first phase of the experiment tested whether wildcard accept headers (such as the complex header sent by OpenAI’s GPTBot) would trigger Markdown delivery.

Testing with 20,000 crawler simulations confirmed that Cloudflare only serves Markdown when it is explicitly requested in the headers via ‘Accept: text/markdown’.

The second phase analyzed a sample of 4,300,723 real-world requests across five domains to determine how often frontier crawlers request Markdown. Out of those requests, only 108,736 (about 2.5%) requested Markdown. Crucially, the frontier bots responsible for the vast majority of AI search traffic never requested Markdown:

• PerplexityBot: 605,811 observations – 0 Markdown requests
• Meta-ExternalAgent: 359,222 observations – 0 Markdown requests
• GPTBot: 260,472 observations – 0 Markdown requests
• OAI-SearchBot: 33,631 observations – 0 Markdown requests
• ClaudeBot: 18,831 observations – 0 Markdown requests

In contrast, only specific specialized or unclassified crawlers requested Markdown:

• ExaSearchBot: 67,578 requests (99.02%)
• ShapBot: 3,588 requests (100%)
• Unclassified bots: 4,615 requests
• Claude-User Impersonators: 248 requests
• GoogleBot impersonators: 32,747 requests

Implications for GEO/AEO

‘While we didn’t study every markdown solution, at least for Cloudflare Agent Markdown, there is zero impact to frontier behavior, citation, or recommendation,’ Maynard concluded. “While we didn’t look at all markdown services, the result for Cloudflare is clear.” said Robert Maynard, Founder of AnswerShare. “They built the pipe, but major AI crawlers aren’t using the faucet. Until AI labs update their scrapers to request text/markdown, enabling the feature yields no real-world impact on frontier AI indexing.

While automated Markdown translation fails to influence key crawlers, organizations looking to meaningfully impact AI engine behavior must look to more direct solutions, such as those provided by AnswerShare.

Manifests, logs and methodology are available at AnswerShare Research.

About AnswerShare

AnswerShare is the pioneer of the AI Translation Layer, helping clients actively shape and influence AI crawler behavior and citation outcomes.

Media Contact Details
Kevin Myers
Email: Send Email
Website: answershare.com

Boston, MA

Riverponds Global Capital, a Boston-based investment research and strategy firm focused on multi-asset analysis and structured investment approaches, today announced plans to increase its investment in technology research and development during the fourth quarter of 2026.

The planned expansion will focus on strengthening Riverponds Global Capital’s quantitative research infrastructure, artificial intelligence capabilities, cross-market data analytics, and risk-management systems. The initiative is intended to support the firm’s ongoing development of technology-enabled investment research and improve the efficiency, consistency, and scalability of its decision-making processes across global markets.

Riverponds Global Capital integrates quantitative modeling, artificial intelligence, and multi-market research into its investment research framework. The firm focuses on areas including global asset allocation, technology and financial markets, semiconductor-related industries, digital assets, and multi-strategy investment research.

Riverponds Global Capital said its next stage of development will place greater emphasis on the technology infrastructure supporting its research process. As global markets become increasingly interconnected and data-intensive, the firm plans to continue investing in quantitative systems, artificial intelligence, and risk analytics to strengthen its research capabilities and maintain a disciplined, adaptive investment framework.

During the fourth quarter, Riverponds Global Capital expects to allocate additional resources to several areas of technology development, including AI-assisted market analysis, quantitative model optimization, data-processing infrastructure, automated risk monitoring, and research tools designed to evaluate opportunities across multiple asset classes.

The firm also plans to enhance the integration of macroeconomic data, market signals, and sector-specific information within its internal research environment. Riverponds Global Capital expects these efforts to support more systematic analysis of equities, technology supply chains, digital assets, and cross-border market opportunities.

The technology investment is part of Riverponds Global Capital’s broader institutional development strategy for 2024–2026. The firm traces the development of its digital research framework to 2018, when its core team began building an online research architecture focused on global macroeconomic analysis and quantitative strategy testing. Between 2021 and 2023, the team continued to develop and test its quantitative models across periods of elevated market volatility. Since 2024, Riverponds Global Capital has expanded its institutional operations and global research capabilities.

Riverponds Global Capital said the fourth-quarter investment will prioritize long-term research capacity rather than short-term product expansion. The company will continue to emphasize data-driven analysis, disciplined risk management, and the application of technology to multi-asset investment research.

About Riverponds Global Capital

Riverponds Global Capital is a Boston-based investment research and strategy firm specializing in multi-asset analysis, quantitative modeling, artificial intelligence, and structured investment approaches. The firm conducts research across global asset allocation, technology and financial markets, semiconductor-related industries, digital assets, and multi-strategy investment opportunities.

Riverponds Global Capital’s research framework combines quantitative analysis, cross-market research, and technology-enabled risk management to support systematic investment decision-making.

Media Contact Details
Luis Brown
Riverponds Global Capital
Email: Send Email
Website: www.24river.com

Board-certified anesthesiologist brings nearly two decades of clinical experience in intravenous therapy, advanced patient monitoring, and scientific research to Alpha Vital Elite Precision Medical IV’s personalized approach to wellness, healthy aging, and support for chronic disease managemen

New York, USA

As intravenous wellness therapies become increasingly common in spas, wellness centers, mobile services, and at-home settings, one question is becoming increasingly important: Who is making the medical decisions, and who is prepared to respond if something goes wrong?

That question lies at the heart of Alpha Vital Elite Precision Medical IV, a physician-directed medical wellness practice founded on individualized patient evaluation, continuous medical monitoring, evidence-informed decision-making, and the direct on-site presence of a physician.

Dr. Violeta Aronov, a board-certified anesthesiologist with nearly two decades of experience administering intravenous medications and monitoring patients, founded Alpha Vital Elite Precision Medical IV to clearly distinguish physician-led medical wellness from the increasingly common IV bar and medspa model.

“The moment a substance enters a patient’s vein, it becomes a medical intervention—not a spa service,” Dr. Aronov said. “Starting an IV is a technical skill that trained nurses perform every day. But determining whether an infusion is medically appropriate, understanding how it may affect the body, and recognizing and managing complications require a physician’s training, clinical judgment, and oversight.”

Bringing Medical Standards Into the Wellness Environment

IV therapy has become increasingly accessible, with consumers seeking infusions for hydration, recovery, wellness support, and healthy aging. As these services grow in popularity, however, Dr. Aronov believes medical oversight and consumer education are more important than ever.

Instead of asking patients to select an infusion from a predetermined menu, Alpha Vital Elite Precision Medical IV begins with an individualized medical assessment.

Dr. Aronov reviews each patient’s relevant medical history, current medications, allergies, laboratory results, recent illnesses, symptoms, and potential risk factors before determining whether an infusion is medically appropriate.

Most importantly, she says, the evaluation must be completed before any form of supportive IV care is considered.

“The first question is not, ‘Which IV should this patient receive?’” Dr. Aronov said. “The first question is, ‘Should this patient receive an IV at all?’ Only after that determination is made should an appropriate supportive approach be considered.”

Her background in anesthesiology significantly shaped that philosophy. Anesthesiologists routinely administer intravenous medications while continuously evaluating how a patient’s heart, blood pressure, breathing, oxygen levels, and overall physiology respond. That experience has made vigilant monitoring, clinical preparedness, and direct physician involvement fundamental to Dr. Aronov’s approach to wellness care.

“A physician’s name on a document is not an emergency plan,” Dr. Aronov said. “What matters is the training, clinical judgment, and physical presence of the physician who can immediately recognize and manage a complication at the patient’s side.”

Five Questions Consumers Should Ask Before IV Therapy

Dr. Aronov encourages consumers to look beyond luxurious surroundings, marketing claims, or extensive infusion menus—and instead examine the medical infrastructure behind the IV service they are considering.

Before undergoing IV therapy, she believes every patient should ask:

1. Who reviewed my medical history and determined that IV therapy is appropriate for me?
2. Who selected the ingredients, dosages, and infusion rate?
3. Who will monitor my heart rate or rhythm, blood pressure, and oxygen level during the infusion?
4. Who is physically present if I experience an adverse reaction?
5. What can that person do before emergency medical services arrive?

At Alpha Vital Elite Precision Medical IV, Dr. Aronov says monitoring vital signs and maintaining immediate access to oxygen, emergency medications, and emergency-response equipment are integral parts of the practice’s safety model. As a physician trained in Advanced Cardiovascular Life Support, she remains physically present to evaluate patients and respond if a patient’s condition changes unexpectedly.

“Calling 911 is important, but it cannot be the entire emergency plan,” Dr. Aronov said. “The body does not wait for an ambulance. The first few minutes matter.”

Dr. Aronov emphasizes that this philosophy is not intended to diminish the essential roles of nurses, nurse practitioners, physician assistants, or other healthcare professionals. Rather, she wants consumers to understand the specific model of care being offered, the level of monitoring available, and who is physically present, medically trained, and prepared to intervene if an unexpected situation develops.

Moving Beyond One-Size-Fits-All Wellness

Personalization has become one of the wellness industry’s most frequently used terms, but Dr. Aronov defines it differently.

In her practice, individualized IV care does not mean simply adding more ingredients to an infusion. It means determining what belongs, what does not, how individual components interact with one another, and whether the patient should receive the IV at all.

“An IV bag is not a smoothie,” Dr. Aronov said. “Every ingredient has its own chemistry, and not every substance belongs in the same bag.”

IV ingredients may have different requirements involving compatibility, concentration, pH, diluent, storage, light protection, stability, and administration rate. Depending on the substances involved, compatibility and stability must be evaluated before components are combined. Some components may require separate preparation or sequential administration.

“These are medication-safety principles—not optional details,” Dr. Aronov said. “Complex IV combinations require appropriate knowledge of compatibility, stability, sequencing, and administration. Placing every requested ingredient into one IV bag for convenience is not personalization. The integrity of every component has to be considered. If you fail to preserve the integrity of the component, what are you actually delivering—the intended substance or simply the promise of it?”

“Individualized, elite IV care is not defined by adding more vials to the same bag or by providing an infusion wherever the patient feels more comfortable,” she continued. “A comfortable environment cannot replace appropriate medical screening, monitoring, emergency preparedness, and clinical judgment. True individualization is about patient safety: removing what does not belong, separating components when necessary, protecting the integrity of what remains, monitoring the patient’s response, and making the safest decision for that individual—even when that decision is not to proceed.”

Alpha Vital Elite Precision Medical IV offers supportive protocols focused on hydration, recovery, healthy aging, general wellness, joint support, digestive wellness, skin support, brain wellness, and support for individuals with chronic health concerns. Each protocol serves as a framework rather than an automatic formula selected from a menu and is considered only after an individualized medical evaluation.

These services are designed to complement—not replace—the care provided by a patient’s primary physician or specialist.

When Common Symptoms May Warrant Medical Evaluation

Dr. Aronov also cautions against addressing broad symptoms without first considering their potential underlying causes.

Fatigue is one example.

“Fatigue is not a diagnosis,” Dr. Aronov said.

Low energy can have many possible causes, including poor sleep, anemia, thyroid disorders, infection, medication side effects, or other conditions that may require appropriate medical evaluation. Dr. Aronov believes wellness treatments should never mask a symptom that warrants further investigation.

“I do not treat the name printed on an IV menu,” she said. “I evaluate the individual sitting in front of me.”

Alpha Vital Elite Precision Medical IV positions its wellness services as supportive care—not as a replacement for primary or specialty care, prescription medications, or established medical treatment. The practice also avoids suggesting that IV therapy can cure disease or reverse biological aging.

“To me, healthy aging means supporting function, resilience, independence, and quality of life—not selling the promise of immortality,” Dr. Aronov said.

Science Before Marketing

Long before entering medicine, Dr. Aronov developed a deep respect for scientific rigor.

She studied biochemistry at Stony Brook University and worked in laboratory research, including at Regeneron Pharmaceuticals, before pursuing medicine and anesthesiology.

“Cells do not respond to marketing,” Dr. Aronov said. “They respond to chemistry, amount, timing, and their surrounding environment.”

Her research background taught her that a scientifically compelling concept does not automatically translate into a demonstrated benefit for patients. Anesthesiology later reinforced another principle: even an appropriate substance can become problematic when administered to the wrong patient, at the wrong dose, too quickly, or in an incompatible combination.

That concern is particularly relevant to the growing wellness-industry trend of placing numerous ingredients into a single IV bag.

“An IV bag is not a smoothie. Adding more ingredients does not automatically create a better treatment,” Dr. Aronov said.

Dr. Aronov emphasizes that substances considered for an infusion must be evaluated not only individually but also for compatibility, stability, concentration, administration rate, and other formulation considerations when combined.

“If you fail to preserve the integrity of a component, what are you actually delivering—the intended substance or simply the promise of it?” she said.

Before recommending any intervention, Dr. Aronov says she considers three fundamental questions: Does it make scientific sense? What does the evidence actually show? Is it medically appropriate for this particular patient?

From Physician to Patient

Dr. Aronov’s approach became deeply personal after her breast cancer diagnosis and mastectomy.

Experiencing illness from the other side of the medical relationship gave her a new understanding of the uncertainty patients face—and of their need for clear answers, thoughtful options, and realistic hope.

“Breast cancer placed me on the other side of medicine,” Dr. Aronov said. “It taught me that patients need hope, but they also deserve honesty. That is why I will never promise a cure or make claims that science cannot support.”

Today, those three perspectives—the laboratory scientist, the anesthesiologist, and the patient—shape the philosophy behind Alpha Vital Elite Precision Medical IV.

As the boundaries between medicine and wellness continue to evolve, Dr. Aronov believes wellness care should not abandon the principles of medical safety simply because it is delivered in an environment that feels more comfortable, luxurious, or consumer-friendly.

“A patient’s home may feel comfortable and familiar, but comfort should never be confused with clinical preparedness,” Dr. Aronov said. “The surroundings may change, but the patient’s physiology and the potential medical risks do not.”

She also emphasizes that professional credentials should be considered alongside the specific training, experience, emergency preparedness, medications, monitoring capabilities, and equipment available in the setting where an infusion is administered.

For Dr. Aronov, convenience should never take priority over patient safety. Alpha Vital Elite Precision Medical IV is built around the belief that an elevated, patient-centered wellness experience and rigorous medical decision-making can coexist without compromising safety.

“Science taught me to remain curious. Anesthesiology taught me precision. Becoming a patient taught me humility,” Dr. Aronov said. “Those three lessons guide every decision I make.”

About Alpha Vital Elite Precision Medical IV

Alpha Vital Elite Precision Medical IV is a physician-directed medical wellness practice led by Dr. Violeta Aronov, a board-certified anesthesiologist. The practice takes a medically guided approach to IV therapy and wellness services, with an emphasis on patient screening, physician oversight, monitoring, safety, and individualized treatment decisions.

Its services are designed to support areas including hydration, recovery, healthy aging, and overall wellness while complementing—not replacing—appropriate primary and specialty medical care. Dr. Aronov works in coordination with rheumatologists, dermatologists, gastroenterologists, primary care physicians, and other treating healthcare professionals when appropriate to provide supportive adjunctive care.

Media Contact Details
Liana Zavo
Email: Send Email